A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTX
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
- To demonstrate that SM03 added to methotrexate (MTX) reduce signs and symptoms of
rheumatoid arthritis (RA) in Chinese RA participants with an inadequate response to MTX.
- To assess the safety of SM03 added to MTX in Chinese RA participants with an inadequate
response to MTX